Smart jab can shrink head and neck cancer tumours within six weeks, trial finds
A new triple-action therapy drug called amivantamab, administered as an injection, has shown promising results in treating recurrent or metastatic head and neck cancer. In a clinical trial, the drug was able to shrink tumors in patients within just six weeks. Head and neck cancer is the sixth most common form of cancer globally, and when it spreads or returns after standard treatment, options are limited. The trial results have been described as "incredibly encouraging" by doctors, as the drug could provide a new treatment option for patients with this type of advanced cancer. The findings suggest that this smart jab could be an effective addition to the available therapies for recurrent or metastatic head and neck cancer.
Source: For the complete article, please visit the original source link below.
